{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:32:03Z","timestamp":1790721123393,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Glioblastoma (GB) is a highly aggressive, difficult to treat brain tumour. Successful treatment, consisting of maximal safe tumour de-bulking, followed by radiotherapy and treatment with the alkylating agent Temozolomide (TMZ), can extend patient survival to approximately 15 months. Combination treatments based on the inhibition of the PI3K pathway, which is the most frequently activated signalling cascade in GB, have so far only shown limited therapeutic success. Here, we use the clinically approved MEK inhibitor Trametinib to investigate its potential use in managing GB. Trametinib has a strong anti-proliferative effect on established GB cell lines, stem cell-like cells and their differentiated progeny and while it does not enhance anti-proliferative and cell death-inducing properties of the standard treatment, i.e. exposure to radiation or TMZ, neither does MEK inhibition block their effectiveness. However, upon MEK inhibition some cell populations appear to favour cell-substrate interactions in a sprouting assay and become more invasive in the Chorioallantoic Membrane assay, which assesses cell penetration into an organic membrane. While this increased invasion can be modulated by additional inhibition of the PI3K signalling cascade, there is no apparent benefit of blocking MEK compared to targeting PI3K.<\/jats:p>","DOI":"10.1038\/s41598-020-64289-6","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T10:05:01Z","timestamp":1588586701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["The limitations of targeting MEK signalling in Glioblastoma therapy"],"prefix":"10.1038","volume":"10","author":[{"given":"Karthika D.","family":"Selvasaravanan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Wiederspohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Hadzalic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Strobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Payer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Karpel-Massler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus D.","family":"Siegelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Eric","family":"Halatsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Michael","family":"Debatin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike-Andrew","family":"Westhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,4]]},"reference":[{"key":"64289_CR1","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nrc2818","volume":"10","author":"JT Huse","year":"2010","unstructured":"Huse, J. T. & Holland, E. C. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10, 319\u2013331 (2010).","journal-title":"Nat Rev Cancer"},{"key":"64289_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987\u2013996 (2005).","journal-title":"N Engl J Med"},{"key":"64289_CR3","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1056\/NEJMra0708126","volume":"359","author":"PY Wen","year":"2008","unstructured":"Wen, P. Y. & Kesari, S. Malignant gliomas in adults. N Engl J Med 359, 492\u2013507, https:\/\/doi.org\/10.1056\/NEJMra0708126 (2008).","journal-title":"N Engl J Med"},{"key":"64289_CR4","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1200\/JCO.2003.05.063JCO.2003.05.063","volume":"21","author":"A Giese","year":"2003","unstructured":"Giese, A., Bjerkvig, R., Berens, M. E. & Westphal, M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21, 1624\u20131636, https:\/\/doi.org\/10.1200\/JCO.2003.05.063JCO.2003.05.063 (2003).","journal-title":"J Clin Oncol"},{"key":"64289_CR5","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature25480","volume":"555","author":"SN Grobner","year":"2018","unstructured":"Grobner, S. N. et al. The landscape of genomic alterations across childhood cancers. Nature 555, 321\u2013327, https:\/\/doi.org\/10.1038\/nature25480 (2018).","journal-title":"Nature"},{"key":"64289_CR6","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/nature07385","volume":"455","author":"Cancer-Genome-Atlas-Research-Network.","year":"2008","unstructured":"Cancer-Genome-Atlas-Research-Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061\u20131068, https:\/\/doi.org\/10.1038\/nature07385 (2008).","journal-title":"Nature"},{"key":"64289_CR7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/82_2010_67","volume":"347","author":"QW Fan","year":"2010","unstructured":"Fan, Q. W. & Weiss, W. A. Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. Curr Top Microbiol Immunol 347, 279\u2013296, https:\/\/doi.org\/10.1007\/82_2010_67 (2010).","journal-title":"Curr Top Microbiol Immunol"},{"key":"64289_CR8","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/neuonc\/nos117","volume":"14","author":"PY Wen","year":"2012","unstructured":"Wen, P. Y., Lee, E. Q., Reardon, D. A., Ligon, K. L. & Alfred Yung, W. K. Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol 14, 819\u2013829, https:\/\/doi.org\/10.1093\/neuonc\/nos117 (2012).","journal-title":"Neuro Oncol"},{"key":"64289_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/2052-8426-2-32","volume":"2","author":"MA Westhoff","year":"2014","unstructured":"Westhoff, M. A. et al. A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy. Molecular and Cellular Therapies 2, 32 (2014).","journal-title":"Molecular and Cellular Therapies"},{"key":"64289_CR10","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.3390\/ijms15033746","volume":"15","author":"MA Westhoff","year":"2014","unstructured":"Westhoff, M. A., Bruhl, O., Nonnenmacher, L., Karpel-Massler, G. & Debatin, K. M. Killing me softly-future challenges in apoptosis research. Int J Mol Sci 15, 3746\u20133767, https:\/\/doi.org\/10.3390\/ijms15033746 (2014).","journal-title":"Int J Mol Sci"},{"key":"64289_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-017-0004-8","volume":"6","author":"J Langhans","year":"2017","unstructured":"Langhans, J. et al. The effects of PI3K-mediated signalling on glioblastoma cell behaviour. Oncogenesis 6, 398, https:\/\/doi.org\/10.1038\/s41389-017-0004-8 (2017).","journal-title":"Oncogenesis"},{"key":"64289_CR12","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.3892\/ijo.2018.4528","volume":"53","author":"S Hasslacher","year":"2018","unstructured":"Hasslacher, S. et al. Inhibition of PI3K signalling increases the efficiency of radiotherapy in glioblastoma cells. Int J Oncol 53, 1881\u20131896, https:\/\/doi.org\/10.3892\/ijo.2018.4528 (2018).","journal-title":"Int J Oncol"},{"key":"64289_CR13","doi-asserted-by":"publisher","first-page":"e0131670","DOI":"10.1371\/journal.pone.0131670","volume":"10","author":"S Str\u00f6bele","year":"2015","unstructured":"Str\u00f6bele, S. et al. A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy. PLoS One 10, e0131670 (2015).","journal-title":"PLoS One"},{"key":"64289_CR14","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/nm.1890","volume":"14","author":"JA Engelman","year":"2008","unstructured":"Engelman, J. A. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nature Medicine 14, 1351 (2008).","journal-title":"Nature Medicine"},{"key":"64289_CR15","doi-asserted-by":"publisher","unstructured":"Sweetlove, M. et al. Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth. Frontiers in Oncology 5, https:\/\/doi.org\/10.3389\/fonc.2015.00135 (2015).","DOI":"10.3389\/fonc.2015.00135"},{"key":"64289_CR16","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1038\/bjc.2012.70","volume":"106","author":"EJ Haagensen","year":"2012","unstructured":"Haagensen, E. J., Kyle, S., Beale, G. S., Maxwell, R. J. & Newell, D. R. The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. British Journal Of Cancer 106, 1386 (2012).","journal-title":"British Journal Of Cancer"},{"key":"64289_CR17","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1158\/0008-5472.can-11-3747","volume":"72","author":"AB Turke","year":"2012","unstructured":"Turke, A. B. et al. MEK Inhibition Leads to PI3K\/AKT Activation by Relieving a Negative Feedback on ERBB Receptors. Cancer Research 72, 3228\u20133237, https:\/\/doi.org\/10.1158\/0008-5472.can-11-3747 (2012).","journal-title":"Cancer Research"},{"key":"64289_CR18","doi-asserted-by":"publisher","first-page":"21124","DOI":"10.1073\/pnas.1314124110","volume":"110","author":"H Ebi","year":"2013","unstructured":"Ebi, H. et al. PI3K regulates MEK\/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. Proceedings of the National Academy of Sciences 110, 21124\u201321129, https:\/\/doi.org\/10.1073\/pnas.1314124110 (2013).","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"64289_CR19","doi-asserted-by":"crossref","unstructured":"Golding, S. E. et al. Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. Cancer Biol Ther 8, 730\u2013738, 7927 (2009).","DOI":"10.4161\/cbt.8.8.7927"},{"key":"64289_CR20","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/bjc.2014.435","volume":"111","author":"S Han","year":"2014","unstructured":"Han, S., Li, Z., Master, L. M., Master, Z. W. & Wu, A. Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin beta1-ERK pathway. Br J Cancer 111, 1400\u20131409, https:\/\/doi.org\/10.1038\/bjc.2014.435 (2014).","journal-title":"Br J Cancer"},{"key":"64289_CR21","doi-asserted-by":"publisher","first-page":"H1956","DOI":"10.1152\/ajpheart.00407.2008","volume":"295","author":"J Liu","year":"2008","unstructured":"Liu, J., Mao, W., Ding, B. & Liang, C. S. ERKs\/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. Am J Physiol Heart Circ Physiol 295, H1956\u20131965, https:\/\/doi.org\/10.1152\/ajpheart.00407.2008 (2008).","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"64289_CR22","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1002\/stem.753","volume":"29","author":"A Sato","year":"2011","unstructured":"Sato, A. et al. MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis. Stem Cells 29, 1942\u20131951, https:\/\/doi.org\/10.1002\/stem.753 (2011).","journal-title":"Stem Cells"},{"key":"64289_CR23","doi-asserted-by":"publisher","first-page":"7398","DOI":"10.1038\/sj.onc.1204899","volume":"20","author":"A Besson","year":"2001","unstructured":"Besson, A., Davy, A., Robbins, S. M. & Yong, V. W. Differential activation of ERKs to focal adhesions by PKC \u00ce\u00b5 is required for PMA-induced adhesion and migration of human glioma cells. Oncogene 20, 7398\u20137407, https:\/\/doi.org\/10.1038\/sj.onc.1204899 (2001).","journal-title":"Oncogene"},{"key":"64289_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/cancers9060057","volume":"9","author":"L Annovazzi","year":"2017","unstructured":"Annovazzi, L., Mellai, M. & Schiffer, D. Chemotherapeutic Drugs: DNA Damage and Repair in Glioblastoma. Cancers 9, 57, https:\/\/doi.org\/10.3390\/cancers9060057 (2017).","journal-title":"Cancers"},{"key":"64289_CR25","doi-asserted-by":"publisher","first-page":"7189","DOI":"10.1074\/jbc.275.10.7189","volume":"275","author":"N Ajenjo","year":"2000","unstructured":"Ajenjo, N. et al. Myeloid Leukemia Cell Growth and Differentiation Are Independent of Mitogen-activated Protein Kinase ERK1\/2 Activation. Journal of Biological Chemistry 275, 7189\u20137197, https:\/\/doi.org\/10.1074\/jbc.275.10.7189 (2000).","journal-title":"Journal of Biological Chemistry"},{"key":"64289_CR26","doi-asserted-by":"publisher","first-page":"23366","DOI":"10.1074\/jbc.272.37.23366","volume":"272","author":"FK Racke","year":"1997","unstructured":"Racke, F. K., Lewandowska, K., Goueli, S. & Goldfarb, A. N. Sustained Activation of the Extracellular Signal-regulated Kinase\/Mitogen-activated Protein Kinase Pathway Is Required for Megakaryocytic Differentiation of K562 Cells. Journal of Biological Chemistry 272, 23366\u201323370, https:\/\/doi.org\/10.1074\/jbc.272.37.23366 (1997).","journal-title":"Journal of Biological Chemistry"},{"key":"64289_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0501-y","volume":"15","author":"C Ciccarelli","year":"2016","unstructured":"Ciccarelli, C. et al. Key role of MEK\/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population. Molecular Cancer 15, 16, https:\/\/doi.org\/10.1186\/s12943-016-0501-y (2016).","journal-title":"Molecular Cancer"},{"key":"64289_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/srep43605","volume":"7","author":"G Riddick","year":"2017","unstructured":"Riddick, G. et al. A Core Regulatory Circuit in Glioblastoma Stem Cells Links MAPK Activation to a Transcriptional Program of Neural Stem Cell Identity. Scientific Reports 7, 43605 (2017).","journal-title":"Scientific Reports"},{"key":"64289_CR29","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/pcmr.12388","volume":"28","author":"AM Menzies","year":"2015","unstructured":"Menzies, A. M. et al. Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion. Pigment Cell Melanoma Res 28, 607\u2013610, https:\/\/doi.org\/10.1111\/pcmr.12388 (2015).","journal-title":"Pigment Cell Melanoma Res"},{"key":"64289_CR30","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nature12441","volume":"501","author":"G Hatzivassiliou","year":"2013","unstructured":"Hatzivassiliou, G. et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature 501, 232\u2013236, https:\/\/doi.org\/10.1038\/nature12441 (2013).","journal-title":"Nature"},{"key":"64289_CR31","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ccr.2014.03.011","volume":"25","author":"P Lito","year":"2014","unstructured":"Lito, P. et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell 25, 697\u2013710, https:\/\/doi.org\/10.1016\/j.ccr.2014.03.011 (2014).","journal-title":"Cancer Cell"},{"key":"64289_CR32","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1158\/1078-0432.CCR-10-2200","volume":"17","author":"AG Gilmartin","year":"2011","unstructured":"Gilmartin, A. G. et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 17, 989\u20131000, https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2200 (2011).","journal-title":"Clin Cancer Res"},{"key":"64289_CR33","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrc4000","volume":"15","author":"CJ Caunt","year":"2015","unstructured":"Caunt, C. J., Sale, M. J., Smith, P. D. & Cook, S. J. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nature Reviews Cancer 15, 577 (2015).","journal-title":"Nature Reviews Cancer"},{"key":"64289_CR34","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00412-018-0659-8","volume":"127","author":"X Sun","year":"2018","unstructured":"Sun, X. & Kaufman, P. D. Ki-67: more than a proliferation marker. Chromosoma 127, 175\u2013186, https:\/\/doi.org\/10.1007\/s00412-018-0659-8 (2018).","journal-title":"Chromosoma"},{"key":"64289_CR35","doi-asserted-by":"publisher","first-page":"7092","DOI":"10.1158\/1078-0432.ccr-09-1349","volume":"15","author":"J Portnow","year":"2009","unstructured":"Portnow, J. et al. The Neuropharmacokinetics of Temozolomide in Patients with Resectable Brain Tumors: Potential Implications for the Current Approach to Chemoradiation. Clinical Cancer Research 15, 7092\u20137098, https:\/\/doi.org\/10.1158\/1078-0432.ccr-09-1349 (2009).","journal-title":"Clinical Cancer Research"},{"key":"64289_CR36","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ijrobp.2004.03.005","volume":"59","author":"TM Pawlik","year":"2004","unstructured":"Pawlik, T. M. & Keyomarsi, K. Role of cell cycle in mediating sensitivity to radiotherapy. International Journal of Radiation Oncology \u00e2\u20ac\u00a2 Biology \u00e2\u20ac\u00a2 Physics 59, 928\u2013942, https:\/\/doi.org\/10.1016\/j.ijrobp.2004.03.005 (2004).","journal-title":"International Journal of Radiation Oncology \u00e2\u20ac\u00a2 Biology \u00e2\u20ac\u00a2 Physics"},{"key":"64289_CR37","doi-asserted-by":"publisher","first-page":"5169","DOI":"10.1038\/onc.2008.148","volume":"27","author":"MA Westhoff","year":"2008","unstructured":"Westhoff, M. A., Zhou, S., Bachem, M. G., Debatin, K. M. & Fulda, S. Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells. Oncogene 27, 5169\u20135181, https:\/\/doi.org\/10.1038\/onc.2008.148 (2008).","journal-title":"Oncogene"},{"key":"64289_CR38","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/imammb\/dqq011","volume":"29","author":"H Hatzikirou","year":"2012","unstructured":"Hatzikirou, H., Basanta, D., Simon, M., Schaller, K. & Deutsch, A. \u2018Go or grow\u2019: the key to the emergence of invasion in tumour progression? Math Med Biol 29, 49\u201365, https:\/\/doi.org\/10.1093\/imammb\/dqq011 (2012).","journal-title":"Math Med Biol"},{"key":"64289_CR39","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1038\/sj.onc.1210850","volume":"27","author":"PC De Witt Hamer","year":"2008","unstructured":"De Witt Hamer, P. C. et al. The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene 27, 2091\u20132096, https:\/\/doi.org\/10.1038\/sj.onc.1210850 (2008).","journal-title":"Oncogene"},{"key":"64289_CR40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1158\/1541-7786.MCR-07-0280","volume":"6","author":"A Li","year":"2008","unstructured":"Li, A. et al. Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol Cancer Res 6, 21\u201330, https:\/\/doi.org\/10.1158\/1541-7786.MCR-07-0280 (2008).","journal-title":"Mol Cancer Res"},{"key":"64289_CR41","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1002\/ijc.29908","volume":"138","author":"M Schneider","year":"2016","unstructured":"Schneider, M. et al. A paired comparison between glioblastoma \u201cstem cells\u201d and differentiated cells. Int J Cancer 138, 1709\u20131718, https:\/\/doi.org\/10.1002\/ijc.29908 (2016).","journal-title":"Int J Cancer"},{"key":"64289_CR42","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ccr.2006.03.030","volume":"9","author":"J Lee","year":"2006","unstructured":"Lee, J. et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9, 391\u2013403, https:\/\/doi.org\/10.1016\/j.ccr.2006.03.030 (2006).","journal-title":"Cancer Cell"},{"key":"64289_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-pathol-011110-130324","volume":"9","author":"TF Cloughesy","year":"2013","unstructured":"Cloughesy, T. F., Cavenee, W. K. & Mischel, P. S. Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol 9, 1\u201325, https:\/\/doi.org\/10.1146\/annurev-pathol-011110-130324 (2013).","journal-title":"Annu Rev Pathol"},{"key":"64289_CR44","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijscr.2017.02.025","volume":"33","author":"R Caruso","year":"2017","unstructured":"Caruso, R., Pesce, A. & Wierzbicki, V. A very rare case report of long-term survival: A patient operated on in 1994 of glioblastoma multiforme and currently in perfect health. International Journal of Surgery Case Reports 33, 41\u201343, https:\/\/doi.org\/10.1016\/j.ijscr.2017.02.025 (2017).","journal-title":"International Journal of Surgery Case Reports"},{"key":"64289_CR45","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2012.03.031","volume":"149","author":"MJ Lee","year":"2012","unstructured":"Lee, M. J. et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149, 780\u2013794, https:\/\/doi.org\/10.1016\/j.cell.2012.03.031 (2012).","journal-title":"Cell"},{"key":"64289_CR46","doi-asserted-by":"crossref","unstructured":"Kast, R. E., Karpel-Massler, G. & Halatsch, M. E. CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide. Oncotarget 5, 8052-8082, 2408 (2014).","DOI":"10.18632\/oncotarget.2408"},{"key":"64289_CR47","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3390\/cancers11060794","volume":"11","author":"F Behling","year":"2019","unstructured":"Behling, F. & Schittenhelm, J. Oncogenic BRAF Alterations and Their Role in Brain Tumors. Cancers 11, 794 (2019).","journal-title":"Cancers"},{"key":"64289_CR48","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/cancers9050052","volume":"9","author":"P Wee","year":"2017","unstructured":"Wee, P. & Wang, Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers 9, 52 (2017).","journal-title":"Cancers"},{"key":"64289_CR49","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3892\/ol.2017.6221","volume":"14","author":"H Xu","year":"2017","unstructured":"Xu, H. et al. Epidermal growth factor receptor in glioblastoma. Oncology letters 14, 512\u2013516 (2017).","journal-title":"Oncology letters"},{"key":"64289_CR50","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12935-018-0565-4","volume":"18","author":"B Haas","year":"2018","unstructured":"Haas, B. et al. Inhibition of the PI3K but not the MEK\/ERK pathway sensitizes human glioma cells to alkylating drugs. Cancer cell international 18, 69\u201369, https:\/\/doi.org\/10.1186\/s12935-018-0565-4 (2018).","journal-title":"Cancer cell international"},{"key":"64289_CR51","doi-asserted-by":"publisher","first-page":"47366","DOI":"10.1074\/jbc.M208284200","volume":"277","author":"H Hotokezaka","year":"2002","unstructured":"Hotokezaka, H. et al. U0126 and PD98059, Specific Inhibitors of MEK, Accelerate Differentiation of RAW264.7 Cells into Osteoclast-like Cells. Journal of Biological Chemistry 277, 47366\u201347372, https:\/\/doi.org\/10.1074\/jbc.M208284200 (2002).","journal-title":"Journal of Biological Chemistry"},{"key":"64289_CR52","doi-asserted-by":"publisher","first-page":"e64169","DOI":"10.1371\/journal.pone.0064169","volume":"8","author":"H Zarkoob","year":"2013","unstructured":"Zarkoob, H., Taube, J. H., Singh, S. K., Mani, S. A. & Kohandel, M. Investigating the Link between Molecular Subtypes of Glioblastoma, Epithelial-Mesenchymal Transition, and CD133 Cell Surface Protein. PLOS ONE 8, e64169 (2013).","journal-title":"PLOS ONE"},{"key":"64289_CR53","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.3892\/ol.2016.4113","volume":"11","author":"Y Iwadate","year":"2016","unstructured":"Iwadate, Y. Epithelial-mesenchymal transition in glioblastoma progression. Oncology Letters 11, 1615\u20131620, https:\/\/doi.org\/10.3892\/ol.2016.4113 (2016).","journal-title":"Oncology Letters"},{"key":"64289_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14791\/btrt.2017.5.1.1","volume":"5","author":"Y Li","year":"2017","unstructured":"Li, Y., Ali, S., Clarke, J. & Cha, S. Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications. Brain tumor research and treatment 5, 1\u20139, https:\/\/doi.org\/10.14791\/btrt.2017.5.1.1 (2017).","journal-title":"Brain tumor research and treatment"},{"key":"64289_CR55","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1161\/STROKEAHA.108.534644","volume":"40","author":"P Narasimhan","year":"2009","unstructured":"Narasimhan, P., Liu, J., Song Yun, S., Massengale Justin, L. & Chan Pak, H. VEGF Stimulates the ERK 1\/2 Signaling Pathway and Apoptosis in Cerebral Endothelial Cells After Ischemic Conditions. Stroke 40, 1467\u20131473 (2009).","journal-title":"Stroke"},{"key":"64289_CR56","doi-asserted-by":"publisher","first-page":"e0165876","DOI":"10.1371\/journal.pone.0165876","volume":"11","author":"L Saryeddine","year":"2016","unstructured":"Saryeddine, L., Zibara, K., Kassem, N., Badran, B. & El-Zein, N. EGF-Induced VEGF Exerts a PI3K-Dependent Positive Feedback on ERK and AKT through VEGFR2 in Hematological In Vitro Models. PLOS ONE 11, e0165876 (2016).","journal-title":"PLOS ONE"},{"key":"64289_CR57","doi-asserted-by":"publisher","first-page":"e56505","DOI":"10.1371\/journal.pone.0056505","volume":"8","author":"D Huveldt","year":"2013","unstructured":"Huveldt, D. et al. Targeting Src Family Kinases Inhibits Bevacizumab-Induced Glioma Cell Invasion. PLOS ONE 8, e56505 (2013).","journal-title":"PLOS ONE"},{"key":"64289_CR58","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.tranon.2014.02.016","volume":"7","author":"J Ishida","year":"2014","unstructured":"Ishida, J. et al. Integrin inhibitor suppresses bevacizumab-induced glioma invasion. Translational oncology 7, 292\u2013302.e291 (2014).","journal-title":"Translational oncology"},{"key":"64289_CR59","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/jcpt.12378","volume":"41","author":"M Ameratunga","year":"2016","unstructured":"Ameratunga, M., McArthur, G., Gan, H. & Cher, L. Prolonged disease control with MEK inhibitor in neurofibromatosis type I-associated glioblastoma. J Clin Pharm Ther 41, 357\u2013359, https:\/\/doi.org\/10.1111\/jcpt.12378 (2016).","journal-title":"J Clin Pharm Ther"},{"key":"64289_CR60","doi-asserted-by":"crossref","unstructured":"Salaroglio, I.C., Mungo, E., Gazzano, E., Kopecka, J. & Riganti, C. ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer. Int J Mol Sci, 20 (2019).","DOI":"10.3390\/ijms20102505"},{"key":"64289_CR61","doi-asserted-by":"crossref","first-page":"29558","DOI":"10.18632\/oncotarget.16365","volume":"8","author":"CT Ishida","year":"2017","unstructured":"Ishida, C. T. et al. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma. Oncotarget 8, 29558\u201329573 (2017).","journal-title":"Oncotarget"},{"key":"64289_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33784-2","volume":"8","author":"E Shang","year":"2018","unstructured":"Shang, E. et al. Dual Inhibition of Bcl-2\/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems. Scientific Reports 8, 15383 (2018).","journal-title":"Scientific Reports"},{"key":"64289_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-25802-0","volume":"8","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. Inhibition of Bcl-2\/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma. Scientific Reports 8, 7373 (2018).","journal-title":"Scientific Reports"},{"key":"64289_CR64","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1111\/bph.14773","volume":"176","author":"ME Halatsch","year":"2019","unstructured":"Halatsch, M. E. et al. Bcl-2\/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug regime against glioblastoma. Br J Pharmacol 176, 3681\u20133694 (2019).","journal-title":"Br J Pharmacol"},{"key":"64289_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1801-0","volume":"10","author":"F Seyfried","year":"2019","unstructured":"Seyfried, F. et al. Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling. Cell Death Dis 10, 571 (2019).","journal-title":"Cell Death Dis"},{"key":"64289_CR66","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1615\/CritRevOncog.2016016987","volume":"21","author":"L Nonnenmacher","year":"2016","unstructured":"Nonnenmacher, L. et al. Cell Death Induction in Cancer Therapy &minus; Past, Present, and Future. Crit Rev Oncog 21, 253\u2013267, https:\/\/doi.org\/10.1615\/CritRevOncog.2016016987 (2016).","journal-title":"Crit Rev Oncog"},{"key":"64289_CR67","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/1535-7163.MCT-13-0052","volume":"12","author":"G Karpel-Massler","year":"2013","unstructured":"Karpel-Massler, G. et al. Combined Inhibition of HER1\/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells. Mol Cancer Ther 12, 1783\u20131795, https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0052 (2013).","journal-title":"Mol Cancer Ther"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64289-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64289-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64289-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T09:49:55Z","timestamp":1670320195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64289-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,4]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["64289"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-64289-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,4]]},"assertion":[{"value":"8 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7401"}}